Safety of Anti‐TNF Therapies in Immune‐Mediated Inflammatory Diseases: Focus on Infections and Malignancy

ABSTRACT The efficacy of anti‐TNF agents in the treatment of multiple immune‐mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long‐term safety profile. Using a literature‐based review of the infectious and malignant complications of anti‐TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti‐TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti‐TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating mind the safety aspects and via a thorough screening and continuous monitoring of the patient. Drug Dev Res, 2015. © 2015 Wiley Periodicals, Inc.
Source: Drug Development Research - Category: Drugs & Pharmacology Authors: Tags: Review Article Source Type: research